A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model

[1]  G. Landreth,et al.  Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[2]  Xiuping Liu,et al.  DNA and protein co-administration induces tolerogenic dendritic cells through DC-SIGN mediated negative signals , 2013, Human vaccines & immunotherapeutics.

[3]  C. Lemere,et al.  MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice , 2013, The Journal of Neuroscience.

[4]  R. Rosenberg,et al.  A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease , 2013, Journal of Neuroimmunology.

[5]  Bin Wang,et al.  Treg Cell Resistance to Apoptosis in DNA Vaccination for Experimental Autoimmune Encephalomyelitis Treatment , 2012, PloS one.

[6]  Yuzhang Wu,et al.  Caveolin-1–Mediated Negative Signaling Plays a Critical Role in the Induction of Regulatory Dendritic Cells by DNA and Protein Coimmunization , 2012, The Journal of Immunology.

[7]  Lianfeng Zhang,et al.  Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer's disease , 2012, Pharmacology Biochemistry and Behavior.

[8]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[9]  K. Mills,et al.  TLR-dependent T cell activation in autoimmunity , 2011, Nature Reviews Immunology.

[10]  W. Klunk.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia , 2011, Neurobiology of Aging.

[11]  G. Puras,et al.  Encapsulation of Aβ(1-15) in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  T. L. Taylor,et al.  Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence , 2011, Journal of Neuroinflammation.

[13]  L. Mucke,et al.  Ablation of Cellular Prion Protein Does Not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice , 2011, The Journal of Neuroscience.

[14]  M. Staufenbiel,et al.  The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects , 2011, The Journal of Neuroscience.

[15]  E. Oviedo-Orta,et al.  Progress in understanding adjuvant immunotoxicity mechanisms. , 2011, Toxicology letters.

[16]  J. Libbey,et al.  Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. , 2011, Vaccine.

[17]  P. Livingston,et al.  Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer , 2011, Expert review of vaccines.

[18]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[19]  J. Buckner.  Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases , 2010, Nature Reviews Immunology.

[20]  E. Siemers,et al.  Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study , 2010, Alzheimer's & Dementia.

[21]  Qinying Zhao,et al.  Safety and pharmacokinetics following a single 10-minute intravenous infusion of the anti-amyloid mAb ponezumab (PF-04360365) in patients with mild to moderate Alzheimer's disease , 2010, Alzheimer's & Dementia.

[22]  R. Sperling,et al.  A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease , 2010, Alzheimer disease and associated disorders.

[23]  W. Schmidt,et al.  Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing , 2009 .

[24]  C. Colton,et al.  Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. , 2009, CNS & neurological disorders drug targets.

[25]  L. Mucke,et al.  Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic Aβ Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice , 2009, The Journal of Neuroscience.

[26]  Jianjun Chen,et al.  A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice , 2009, BMC infectious diseases.

[27]  V. Vasilevko,et al.  Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice , 2008, Journal of Neuroinflammation.

[28]  R. Nitsch,et al.  Targeting β-amyloid pathology in Alzheimer’s disease with Aβ immunotherapy , 2008, Neurotherapeutics.

[29]  Lin Zhao,et al.  Induction of Adaptive T Regulatory Cells That Suppress the Allergic Response by Coimmunization of DNA and Protein Vaccines1 , 2008, The Journal of Immunology.

[30]  M. Battaglia,et al.  Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans , 2007, Nature Reviews Immunology.

[31]  Changcai Wang,et al.  Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease , 2007 .

[32]  R. Ferrante,et al.  Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide* , 2007, Journal of Biological Chemistry.

[33]  D. Wilcock,et al.  Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. , 2007, Neuroscience.

[34]  Hartwig Wolburg,et al.  Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.

[35]  C. Lemere,et al.  Short Amyloid-β (Aβ) Immunogens Reduce Cerebral Aβ Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an Aβ-Specific Cellular Immune Response , 2006, The Journal of Neuroscience.

[36]  Alun Williams,et al.  Interferon-γ increases neuronal death in response to amyloid-β1-42 , 2006, Journal of Neuroinflammation.

[37]  S. Barger,et al.  Journal of Neuroinflammation Interleukin-1 Mediates Alzheimer and Lewy Body Pathologies , 2022 .

[38]  Fuchun Zhang,et al.  Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines. , 2005, Virology.

[39]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[40]  Kefei Chen,et al.  Behavioral phenotypes of amyloid‐based genetically modified mouse models of Alzheimer's disease , 2005, Genes, brain, and behavior.

[41]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[42]  L. Jenkins,et al.  Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.

[43]  Zheng Feng,et al.  Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease , 2004, Journal of pineal research.

[44]  Manuel Buttini,et al.  Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. , 2004, The American journal of pathology.

[45]  Dave Morgan,et al.  Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.

[46]  R. Motter,et al.  Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Comi,et al.  Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. , 2003, Brain : a journal of neurology.

[48]  J. Trojanowski,et al.  IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques , 2002, Brain Research.

[49]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[50]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[51]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[53]  Q. Chuan,et al.  Establishment of the transgenic model of Alzheimers disease , 2000, Neurobiology of Aging.

[54]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[55]  R. Veerhuis,et al.  Cytokines Associated with Amyloid Plaques in Alzheimer's Disease Brain Stimulate Human Glial and Neuronal Cell Cultures to Secrete Early Complement Proteins, But Not C1-Inhibitor , 1999, Experimental Neurology.

[56]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[57]  C. Kensil,et al.  QS-21: a water-soluble triterpene glycoside adjuvant. , 1998, Expert opinion on investigational drugs.

[58]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[59]  J. M. Koolhaas,et al.  Long-term changes in open field behaviour following a single social defeat in rats can be reversed by sleep deprivation , 1996, Physiology & Behavior.

[60]  H. Weiner,et al.  Antigen‐specific TGF‐β1 Secretion with Bovine Myelin Oral Tolerization in Multiple Sclerosis , 1996, Annals of the New York Academy of Sciences.

[61]  K. Liang,et al.  Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris water maze. , 1994, The Chinese journal of physiology.

[62]  C. Lallemand,et al.  Adjuvant activity of cytokines. , 2010, Methods in molecular biology.

[63]  T. Nomura,et al.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. , 2006, Current topics in microbiology and immunology.